Miransertib
Miransertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against RAC-gamma serine/threonine-protein kinase, RAC-beta serine/threonine-protein kinase, and RAC-alpha serine/threonine-protein kinase.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Proteus syndrome | D016715 | Orphanet_744 | Q87.3 | 1 | 1 | — | — | 1 | 3 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 2 | — | — | — | — | 2 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | 1 | — | — | — | — | 1 | |
| Lymphoma | D008223 | C85.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Growth disorders | D006130 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MIRANSERTIB |
| INN | miransertib |
| Description | Miransertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against RAC-gamma serine/threonine-protein kinase, RAC-beta serine/threonine-protein kinase, and RAC-alpha serine/threonine-protein kinase. |
| Classification | Small molecule |
| Drug class | serine/threonine kinase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 101409-76-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297188 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | T1DQI1B52Y (ChemIDplus, GSRS) |
Target
Agency Approved
AKT3
AKT3
AKT2
AKT2
AKT1
AKT1
Organism
Homo sapiens
Gene name
AKT3
Gene synonyms
PKBG
NCBI Gene ID
Protein name
RAC-gamma serine/threonine-protein kinase
Protein synonyms
PKB gamma, Protein kinase Akt-3, Protein kinase B gamma, RAC-gamma serine/threonine protein kinase, RAC-PK-gamma, STK-2, v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma)
Uniprot ID
Mouse ortholog
Akt3 (23797)
RAC-gamma serine/threonine-protein kinase (Q9WUA6)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 120 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more